

**Ablación por radiofrecuencia en fertilidad.**

**Uso en adenomiosis**

**Dr. Angel Santalla  
Hospital Universitario Virgen de las Nieves. Granada.**

# ¿Cómo funciona la ablación por RF?

International Journal of Gynecology and Obstetrics (2007) 99, 9–13

available at [www.sciencedirect.com](http://www.sciencedirect.com)

 ScienceDirect

[www.elsevier.com/locate/ijgo](http://www.elsevier.com/locate/ijgo)



www.ijgo.org

CLINICAL ARTICLE

## Pathologic evaluation of uterine leiomyoma treated with radiofrequency ablation

Xin Luo<sup>a,\*</sup>, Yuan Shen<sup>a</sup>, Wen-Xia Song<sup>b</sup>, Pei-wen Chen<sup>b</sup>,  
Xing-mei Xie<sup>a</sup>, Xiao-yu Wang<sup>a</sup>



<sup>a</sup> Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, China  
<sup>b</sup> Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, China

**Table.** Tissue reaction for various degrees of thermal injury


| Temperature (°C) | Tissue reaction                               |
|------------------|---|
| 42               | More susceptible to chemotherapy or radiation |
| 45               | Irreversible cellular damage in several hours |
| 50–55            | Irreversible cellular damage in 4–6 min       |
| 60–100           | Coagulation of tissue                         |
| 100–110          | Vaporization and carbonization of tissue      |

For successful ablation, the tissue temperature should be maintained in the ideal range, which is 60–100°C.


## Laparoscopico ACCESA®



## Transcervical SONATA®



## Vaginal “Mooving shot”



Elaboración propia





## Quality of Life, Adverse Events, and Reintervention Outcomes after Laparoscopic Radiofrequency Ablation for Symptomatic Uterine Fibroids: A Meta-Analysis

Letao Lin, MD, Haocheng Ma, MD, Jian Wang, MD, Haitao Guan, MD, Min Yang, MD, Xiaoqiang Tong, MD,

Yinghua Zou, MD\*

Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China (all authors)

Journal of Laparoscopic & Advanced Surgical Techniques, Vol. 29, No. 12 | Full Reports

Free Access

## Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies

Linda D. Bradley, Resad P. Pasic, and Larry E. Miller

Published Online: 3 Dec 2019 | <https://doi.org/10.1089/lap.2019.0550>

LAP-2018-0293-ver9-Rev\_1P:3d 06/25/18 2:01pm Page 1

LAP-2018-0293-ver9-Rev\_1P

Type: research article

Full Reports

JOURNAL OF LAPAROSCOPIC & ADVANCED SURGICAL TECHNIQUES  
Volume 09, Number 09, 2019  
© Mary Ann Liebert, Inc.  
DOI: 10.1089/lap.2019.0550

## Transvaginal Radiofrequency Ablation of Myomas: Technique, Outcomes, and Complications

Victoria E. Rey, MD, Rocío Labrador, MD, María Falcón, MD, and José Luis García-Benito, MD



Original Article

## Efficacy, Complications, and Factors Predictive of Response to Treatment with Transvaginal Radiofrequency Ablation for Symptomatic Uterine Myomas

Ángel Santalla-Hernández, PhD, Mariña Naveiro-Fuentes, PhD, Rebeca Benito-Villena, MD, María Setefilla López-Criado, PhD, Aida González-Paredes, PhD, and Jorge Fernández-Parra, PhD

From the Department of Obstetrics and Gynecology, Virgen de las Nieves University Hospital, Granada, Spain

ELSEVIER

Contents lists available at ScienceDirect

**European Journal of Obstetrics & Gynecology and Reproductive Biology: X**

journal homepage: [www.elsevier.com/locate/ejog-ox](http://www.elsevier.com/locate/ejog-ox)

Complications of transvaginal radiofrequency ablation of fibroids: A 5-year experience

Ángel Santalla-Hernández<sup>1,2</sup>, Mariña Naveiro-Fuentes<sup>1</sup>, Rebeca Benito-Villena<sup>1</sup>, Jesús Villegas-Alcazar<sup>1</sup>, María Setefilla López-Criado<sup>1</sup>, Ana Lara-Serrano<sup>1</sup>, Jorge Fernández-Parra<sup>1,2</sup>, Juan Luis Alcázar<sup>1</sup>, Irene Pelayo-Delgado<sup>1</sup>

<sup>1</sup> Obstetrics and Gynecology Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain

Journal of Gynecology Obstetrics and Human Reproduction 53 (2014) 102812

Contents lists available at ScienceDirect

**Journal of Gynecology Obstetrics and Human Reproduction**

journal homepage: [www.elsevier.com/locate/jogoh](http://www.elsevier.com/locate/jogoh)

Original Article

Outcomes of transvaginal radiofrequency ablation for symptomatic leiomyomas

Daniela Escalante Ariza<sup>1</sup>, Isabel Rodríguez García, José Alejandro Ávila Cabeja, Erzer Hidalgo Carmona

From the Departments of Obstetrics and Gynecology, San Guillén University Hospital, Avenida del Guadalquivir s/n, Sevilla, 41015, Spain


ORIGINAL ARTICLE

## Clinical outcomes after 2-year follow-up of transvaginal radiofrequency ablation of symptomatic uterine fibroids

Ángel Santalla-Hernández<sup>1</sup> | Mariña Naveiro-Fuentes<sup>1</sup> |  
María Setefilla López-Criado<sup>1</sup> | Roi Naveiro-Flores<sup>2</sup> | Jorge Fernández-Parra<sup>1</sup>

Estudio multicéntrico español para evaluar eficacia, seguridad, reproducibilidad y factores pronósticos de respuesta al tratamiento de la ablación de miomas por radiofrecuencia vía vaginal.





Reducción media volumen mioma 12 m 70%

Reducción sangrado menstrual 50%

Necesidad de tratamiento medico adicional 10%


Desaparición completa 40%

Mejora escalas SSS / UFS-QoL

Tasa complicaciones 2-8% (95% CI-Dindo I)

Edad y volumen inicial del mioma factores pronosticos de respuesta al tratamiento

**Resultados obstétricos tras  
ablación por radiofrecuencia**





Original Article

Case Series of Reproductive Outcomes after Laparoscopic Radiofrequency Ablation of Symptomatic Myomas

Jay M. Berman, MD, Abraham Shashoua, MD, Christopher Olson, MD, Sara Brucker, MD, John A. Thiel, MD, and Bala Bhagavath, MD

Article

Transcervical Fibroid Ablation (TFA): Update on Pregnancy Outcomes

Leslie Hansen-Lindner 1, Juliette Schmid-Lossberg 2 and David Toub 3,\*

RBMO REVIEW Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids. Biography of Shen Chuen Khaw.

Research Article



Obstetric outcome after ultrasound guided transvaginal radiofrequency ablation of uterine myomas

Abstract

Volume 14 Issue 6 - 2023

Purpose: The objective is to report the obstetric outcome of 8 pregnancies with uterine fibroids who conceived after RFA.

Methods: A study was conducted on 115 women with symptomatic uterine fibroids undergoing transvaginal RFA using a bipolar radiofrequency generator and an internally cooled electrode. Data on pregnancies and outcomes were collected.

Santalla-Hernández Angel, Manzanares Sebastián, Naveiro-Fuentes Mariña, López-Criado María Setefilla, Fernández-Parra Jorge

Original Research

Pregnancy Outcomes After Laparoscopic Radiofrequency Ablation of Uterine Leiomyomas Compared With Myomectomy

Antoinette Allen, MD, Michael Schembri, BS, Ram Parvataneni, MD, MPH, L. Elaine Waetjen, MD, Shira Varon, MD, Naghmeh Salamat-Saberi, MD, Shawn Tassone, MD, PhD, Nicole Williams, MD, Kimberly A. Kho, MD, MPH, and Vanessa L. Jacoby, MD, MAS

Original Research

Pregnancy Outcomes After Transvaginal Radiofrequency Ablation of Leiomyomas

Victoria E. Rey, MD, Maria M. Falcon, MD, Ida Ferrara, MD, and Gabriel Yanes, MD



Downloaded from CMCX

# ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

NUMBER 228

(Replaces Practice Bulletin Number 96, August 2008)

Committee on Practice Bulletins—Gynecology. This Practice Bulletin was developed by the ACOG Committee on Practice Bulletins—Gynecology in collaboration with Elizabeth A. Stewart, MD; Marisa R. Adelman, MD; and Vanessa L. Jacoby, MD, MAS.

## Management of Symptomatic Uterine Leiomyomas

### Radiofrequency Ablation

Laparoscopic radiofrequency ablation can be considered as a minimally invasive treatment option for the management of symptomatic leiomyomas in patients who desire uterine preservation and are counseled about the limited available data on reproductive outcomes. Radiofrequency ablation (RFA) can be delivered by a laparoscopic, transvaginal, or transcervical approach, using ultrasound guidance to induce coagulative necrosis in targeted uterine leiomyomas. All of the approaches are similarly effective in reducing uterine leiomyoma volume and in improving quality of life metrics, but the laparoscopic approach has been studied the most rigorously (61). Although RFA is a

long-term follow up (up to 36 months) (61). Complication reporting was highly inconsistent, but no serious procedural complications such as death or injury to visceral structures was reported in any of the included studies. Neither meta-analysis reported outcomes on menstrual bleeding.

In a case-series of 30 pregnancies after laparoscopic RFA, there were 26 full-term live births and four pregnancy losses (64). Although in this small case series there were no cases of preterm delivery, uterine rupture, placental abruption, placenta accreta, or intrauterine growth restriction (64), sample size precludes any definitive conclusions about risk or incidence of pregnancy complications.

## AAGL practice committee (2025)



### Review Article

### Radiofrequency Ablation for the Treatment of Uterine Fibroids: A Systematic Review and Meta-Analysis by the AAGL Practice Committee

Innie Chen, MD, MPH, Jay M. Berman, MD, Ethan M. Balk, MD, MPH, Ian J. Saldanha, MBBS, MPH, PhD, Emilie Kowalczewski, MSc, Johnny Yi, MD, Salena Zanotti, MD, Mariam Al Hilli, MD, and Kimberly A. Kho, MD, MPH

### PRECIS

Despite limitations in the body of evidence, radiofrequency ablation for the treatment of uterine fibroids has potential to improve uterine bleeding, bulk symptoms, and quality of life.




Ablacion de miomas  
por radiofrecuencia en fertilidad

# ¿Puede la ablación del mioma por RF afectar al endometrio?

## Journal Pre-proof

Transvaginal radiofrequency ablation: a therapeutic option for managing symptomatic uterine fibroids in women with reproductive desires.

M<sup>a</sup> Eugenia Marín Martínez, MD, Sara Cruz-Melguizo, MD PhD, Gema Vaquero Argüello, MD, Virginia Engels Calvo, MD PhD, M<sup>a</sup> Luisa De la Cruz Conty, PhD, Tirso Pérez Medina, MD PhD



© 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.



- 19 pacientes deseos genésicos inmediatos 14 (73,68%) embarazos 2 años.
- Tiempo medio hasta embarazo 12 meses
- 12% abortos.
- Resultados obstétricos y neonatales normales.

# Ablación po RF vaginal y FIV /ICSI: Dra Maria Cerrillo (IVI Madrid)

## RF vaginal

34 patients FIGO 2-3 de < 4 cm

### Resultados



Se confirmó una media de descenso al mes de un 54% y de un 88% a los 3 meses

**33<sup>o</sup>** Congreso Nacional Sociedad Española de Fertilidad **Bilbao 2022** del 4 al 6 de mayo Palacio Euzkalduna

**8<sup>o</sup>** Congreso Nacional de Enfermería de la Reproducción

#SEF22



### Resultados

- Un 60% (9/15 pacientes) realizaron tratamientos.
- 5 realizaron tratamiento con ovocitos propios y 4 ovidonación

| Resultados Ciclos           |     |
|-----------------------------|-----|
| Tasa gestación              | 55% |
| Tasa de aborto              | 18% |
| Tasa de gestación evolutiva | 39% |

●2024: 34 PACIENTES (IVF/OD)

3 meses tras RF

-No diferencias tasa de embarazo

-No diferencias tasa de aborto.

# Afectación endometrial tras RF

(U.H Virgen de las Nieves, Granada)

Ablación de mioma por RF

Biopsia endometrial 0, 3 y 6 meses

Cycle pase  
Distribution and shape of glands  
Apocrine discharge  
Focal/diffuse stromal edema  
Endometrial hyperplasia



Miomectomía hsc


Evaluacion cambios endometrio :  
Hematoxilina-eosina  
Tasa endometritis crónica  
Inmunohistoquímica

MUM1  
CD138  
Estrogen receptors  
Progesterone receptors  
CD56  
CD34  
Ki67  
VEGF  
p53  
BCL2

Febrero 2025: 40 casos grupo RF:



0 pacientes mostraron cambio en los parámetros histológicos e inmunohistoquímicos evaluados tras ablación por radiofrecuencia

# ABLACIÓN POR RADIOFRECUENCIA EN ADENOMIOSIS




MUSA consensus

295



## Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis

Jang-Hyun Nam 

*Naam Clinic for Women's Health, Seoul, Republic of Korea*

SCIENTIFIC PAPER

JSLs


## Laparoscopic Radiofrequency Thermal Ablation for Uterine Adenomyosis

Stefano Scarperi, MD, Giovanni Pontrelli, MD, Colette Campana, MD, Martin Steinkasserer, MD, Alfredo Ercoli, MD, Luca Minelli, MD, Valentino Bergamini, MD, Marcello Ceccaroni, MD, PhD

Surgical Endoscopy (2022) 36:5803–5811  
<https://doi.org/10.1007/s00464-021-08984-z>



## Heat can treat: long-term follow-up results after uterine-sparing treatment of adenomyosis with radiofrequency thermal ablation in 60 hysterectomy candidate patients

Anna Katarzyna Stepniewska<sup>1</sup>  · Silvia Baggio<sup>1</sup> · Roberto Clarizia<sup>1</sup> · Francesco Bruni<sup>1</sup> · Giovanni Roviglione<sup>1</sup> · Matteo Ceccarello<sup>1</sup> · Maria Manzone<sup>1</sup> · Massimo Guerriero<sup>2,3</sup> · Marcello Ceccaroni<sup>1</sup>

Chu et al. *Journal of Ovarian Research* (2024) 17:16  
<https://doi.org/10.1186/s13048-023-01320-0>

Journal of Ovarian Research

RESEARCH

Open Access

## Effects of different treatment methods on clinical efficacy and fertility outcomes of patients with adenomyosis

Zhaoping Chu<sup>1\*</sup>, Ligang Jia<sup>1</sup>, Jun Dai<sup>2</sup>, Qi Wu<sup>1</sup>, Fei Tian<sup>1</sup> and Suning Bai<sup>1</sup>



International Journal of Hyperthermia

ISSN: (Print) (Online) Journal homepage: [www.tandfonline.com/journals/ihyt20](http://www.tandfonline.com/journals/ihyt20)

## Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis


Xiao Liang Lin, Ning Hai, Jing Zhang, Zhi Yu Han, Jie Yu, Fang Yi Liu, Xue Juan Dong & Ping Liang

CEOG Clinical and Experimental  
Obstetrics & Gynecology

## Clinical evaluation of three methods in the treatment of adenomyosis

Sha A Dai Ti, Wu Fu Er, Zhao Lei, A Yi Nu Er, Mai Su Ti, Gu Li Na, A Ba Bai Ke Li

*First Affiliated Hospital of Xinjiang Medical University Gynecology, Urumqi (China)*



International Journal of Hyperthermia

ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/ihyt20>

## Transcervical radiofrequency ablation of focal adenomyosis: pilot results



International Journal of Women's Health

ISSN: (Print) (Online) Journal homepage: [www.tandfonline.com/journals/djwh20](http://www.tandfonline.com/journals/djwh20)

## An Updated Review of Thermal Ablation Technology for Uterine Fibroids and Adenomyosis: Focusing on Protecting Fertility

Qing Zhang, Xiaowen Liang & Zhiyi Chen

Systematic Review

## Radiofrequency Ablation for Adenomyosis

Ioannis Dedes <sup>1,\*</sup>, Georgios Kolovos <sup>1</sup>, Fruscalzo Arrigo <sup>2</sup>, David Toub <sup>3</sup>, Cloé Vaineau <sup>1</sup>, Susanne Lanz <sup>1</sup>, Sara Imboden <sup>1</sup>, Anis Feki <sup>2</sup> and Michael D. Mueller <sup>1</sup>

*J. Clin. Med.* **2023**, *12*, 3069. <https://doi.org/10.3390/jcm12093069>

7 estudios: 396 pacientes. (Tc / LPS RF).

Seguimiento 12-50 meses.

75% adenomiosis focal

Complicaciones leves (Clavien Dindo I) 9%

Table 1. Study Characteristics.

| Study                        | No. of Patients | Loss to Follow Up | NIH Quality Assessment |
|------------------------------|-----------------|-------------------|------------------------|
| Lin, X.L., 2020 [21]         | 65              | 0%                | good                   |
| Nam, J.H., 2020 [24]         | 81              | 33.8%             | fair                   |
| Hai, N., 2017 [23]           | 81              | 6.9%              | good                   |
| Hai, N., 2021 [25]           | 64              | 12.3%             | good                   |
| Scarperi, S., 2015 [22]      | 15              | 33%               | fair                   |
| Stepniewska, A.K., 2022 [19] | 60              | 0%                | good                   |
| Dai Ti, S.A., 2018 [20]      | 30              | n/a               | poor                   |

Table 2. Main outcome on pain.

| Outcome Parameter       | Weighted Mean | SD     | No. of Patients |
|-------------------------|---------------|--------|-----------------|
| Pain Score, adj. (0–10) | −63.4%        | ±9.0%  | n = 366         |
| SSS <sup>1</sup>        | −59.1%        | ±16.6% | n = 210         |

<sup>1</sup> Symptom Severity Score.

Reducción media volumen lesiones - 61% (±20%)

Reducción media volumen uterino 46% (± 11,9%)

Tasa de reintervención (18% -38.5%) (HT 10,8%)

41 embarazos tras tratamiento ( TE : 50%)


Resultados obstétricos y neonatales normales.

## Image-guided thermal ablation in the management of symptomatic adenomyosis: a systematic review and meta-analysis

Lu Liu, Tianfu Wang and Baiying Lei

**Table 2.** Meta-analysis results of the VAS, SSS, QoL and menorrhagia severity scores of HIFU, PMWA and RFA for symptomatic adenomyosis.

| Outcome measures                            | No. of studies | SMD (95% CI)                |  | <i>p</i> Value | <i>I</i> <sup>2</sup> , % | No. of patients |
|---|----------------|-----------------------------|--|----------------|---------------------------|-----------------|
|   |                | Baseline vs. post-operation |  |                |                           |                 |
| <b>VAS scores</b>                           |                |                             |  |                |                           |                 |
| HIFU  | 14             | 2.59 (2.11, 3.06)           |  | <.0001         | 93.7                      | 1026            |
| PMWA  | 5              | 4.27 (2.87, 5.68)           |  | <.0001         | 97.1                      | 371             |
| RFA   | 3              | 3.64 (1.71, 5.57)           |  | <.0001         | 95.9                      | 161             |
| Overall                                     | 22             | 3.14 (2.65, 3.63)           |  | <.0001         | 95.8                      | 1558            |
| <b>SSS scores</b>                           |                |                             |  |                |                           |                 |
| HIFU  | 9              | 2.14 (1.56, 2.72)           |  | <.0001         | 90.2                      | 1091            |
| PMWA  | 3              | 1.45 (0.47, 2.44)           |  | .004           | 94.4                      | 188             |
| RFA   | 2              | 2.15 (-0.03, 4.33)          |  | .053           | 98.1                      | 146             |
| Overall                                     | 14             | 1.96 (1.53, 2.39)           |  | <.0001         | 92.9                      | 1425            |
| <b>Reduction rate of uterine volume</b>     |                |                             |  |                |                           |                 |
| HIFU  | 7              | 0.336 (0.180, 0.491)        |  | <.0001         | 95.9                      | 1412            |
| PMWA  | 3              | 0.468 (0.170, 0.758)        |  | .002           | 96.0                      | 255             |
| RFA   | 2              | 0.440 (0.360, 0.520)        |  | <.0001         | 0                         | 146             |
| Overall                                     | 12             | 0.388 (0.274, 0.501)        |  | <.0001         | 95.2                      | 1813            |
| <b>Reduction rate of adenomyosis volume</b> |                |                             |  |                |                           |                 |
| HIFU  | 7              | 0.451 (0.354, 0.549)        |  | <.0001         | 84.4                      | 1272            |
| PMWA  | 2              | 0.745 (0.677, 0.821)        |  | <.0001         | 0                         | 138             |
| RFA   | 3              | 0.613 (0.525, 0.702)        |  | <.0001         | 22.8                      | 161             |
| Overall                                     | 11             | 0.546 (0.472, 0.620)        |  | <.0001         | 83.4                      | 1537            |
| <b>Relief rate of dysmenorrhea</b>          |                |                             |  |                |                           |                 |
| HIFU  | 5              | 0.842 (0.808, 0.876)        |  | <.0001         | 30.3                      | 665             |
| PMWA  | 3              | 0.897 (0.827, 0.967)        |  | <.0001         | 61.9                      | 188             |
| RFA   | 2              | 0.892 (0.799, 0.985)        |  | <.0001         | 42.7                      | 95              |
| Overall                                     | 10             | 0.868 (0.833, 0.904)        |  | <.0001         | 61.1                      | 948             |





## Heat can treat: long-term follow-up results after uterine-sparing treatment of adenomyosis with radiofrequency thermal ablation in 60 hysterectomy candidate patients

Anna Katarzyna Stepniewska<sup>1</sup> · Silvia Baggio<sup>1</sup> · Roberto Clarizia<sup>1</sup> · Francesco Bruni<sup>1</sup> · Giovanni Roviglione<sup>1</sup> · Matteo Ceccarello<sup>1</sup> · Maria Manzone<sup>1</sup> · Massimo Guerriero<sup>2,3</sup> · Marcello Ceccaroni<sup>1</sup>

- 60 pacientes . Seguimiento 50 meses
- Focal o adenomioma: 77%
- 65% adenomiosis + endometriosis (análisis multivariante)
- Reducción adenomiosis : 64%
- Desaparición completa: 20%
- 2 embarazos
- Histerectomía: 13% (media 48 meses)
- Subgrupo solo adenomiosis (24 pac):
  - Pacientes con SMA 67%----24%
  - Reducción media puntuación NRS 7,06---- 4



RESEARCH

Open Access



## Effects of different treatment methods on clinical efficacy and fertility outcomes of patients with adenomyosis

Zhaoping Chu<sup>1\*</sup>, Ligang Jia<sup>1</sup>, Jun Dai<sup>2</sup>, Qi Wu<sup>1</sup>, Fei Tian<sup>1</sup> and Suning Bai<sup>1</sup>

140 pacientes con adenomiosis  
4 grupos:

- LPS
- LPS + GnRh an.
- RF
- RF + GnRh an.

**Table 2** Comparison of VAS scores, menstrual volume, and uterine volume

| Groups            | Time             | VAS score      | Menstrual volume (ml) | Uterine volume (cm <sup>3</sup> ) |
|-------------------|------------------|----------------|-----------------------|-----------------------------------|
| Group A<br>(n=35) | Before treatment | 5.46 ± 1.29    | 296.76 ± 31.19        | 216.17 ± 10.80                    |
|                   | After treatment  | 2.89 ± 0.93*   | 104.72 ± 12.86*       | 155.91 ± 7.24*                    |
| Group B<br>(n=35) | Before treatment | 5.66 ± 1.26    | 291.52 ± 30.66        | 218.32 ± 11.78                    |
|                   | After treatment  | 1.80 ± 0.68*#  | 85.43 ± 8.26*#        | 135.08 ± 6.23*#                   |
| Group C<br>(n=35) | Before treatment | 5.69 ± 1.43    | 296.28 ± 30.84        | 217.13 ± 10.26                    |
|                   | After treatment  | 1.89 ± 0.63*#  | 86.34 ± 8.11*#        | 136.46 ± 6.20*#                   |
| Group D<br>(n=35) | Before treatment | 5.43 ± 1.31    | 294.21 ± 31.05        | 218.12 ± 10.87                    |
|                   | After treatment  | 0.66 ± 0.48*#& | 52.55 ± 5.03*#&       | 103.30 ± 5.21*#&                  |

Note: \*  $P < 0.05$  vs. before treatment; #  $P < 0.05$  vs. group A; \$  $P < 0.05$  vs. group B; &  $P < 0.05$  vs. group C

RESEARCH

Open Access



# Effects of different treatment methods on clinical efficacy and fertility outcomes of patients with adenomyosis

Zhaoping Chu<sup>1\*</sup>, Ligang Jia<sup>1</sup>, Jun Dai<sup>2</sup>, Qi Wu<sup>1</sup>, Fei Tian<sup>1</sup> and Suning Bai<sup>1</sup>

**Table 3** Comparison of curative effects

| Groups           | Obviously effective | Effective   | Ineffective | Total effective rate |
|------------------|---------------------|-------------|-------------|----------------------|
| Group A (n = 35) | 12 (34.29%)         | 13 (37.14%) | 10 (28.57%) | 71.43                |
| Group B (n = 35) | 16 (45.71%)         | 12 (34.29%) | 7 (20.00%)  | 80                   |
| Group C (n = 35) | 17 (48.57%)         | 12 (34.29%) | 6 (17.14%)  | 82.86                |
| Group D (n = 35) | 24 (68.57%)         | 11 (31.43%) | 0           | 100.00*#§            |

Note: \*  $P < 0.05$  vs. group A; #  $P < 0.05$  vs. group B; §  $P < 0.05$  vs. group C

## Conclusiones

- RF en adenomiosis focal buena eficacia y presenta mínimas complicaciones.
- Embarazos no han mostrado complicaciones obstétricas o neonatales.
- Necesidad de más información acerca resultados a largo plazo.
- La falta de alternativas eficaces para tratar la adenomiosis merece que sigamos explorando resultados.

MUCHAS GRACIAS

